Black-Tie Event Held at the Tampa Bay History Center
TAMPA, Fla. – December 13, 2014 – Romark Laboratories announced today that it is celebrating “20 Years Making History, 1994-2014 ” this evening at a black-tie anniversary celebration held at the Tampa Bay History Center in Tampa.
Approximately 150 employees, research scientists, directors, shareholders, business partners and special guests from across the United States and Europe will attend the event.
"Twenty years is an important milestone," said Jean-François Rossignol, M.D., Ph.D., Chairman and Chief Science Officer and co-founder of Romark. "More important, however, are the things we have been able to accomplish during those twenty years – 58 peer-reviewed publications of our research, more than 600 patents, three New Drug Applications approved by FDA, and more than 100 million people who have benefitted from treatment with our medicines."
Romark was founded in 1994 and has had its headquarters in Tampa throughout its twenty-year history. The Company’s research and development and pharmaceutical operations have spanned six continents, and today the Company has more than 150 employees in the United States and Europe.
“This will be a special occasion,” added Marc Ayers, President and Chief Executive Officer and co-founder of Romark. “We look forward to revisiting our history and celebrating our achievements as well as the opportunities that lie ahead of us.”
Following Rossignol’s experience in infectious diseases, in its early years, Romark focused on developing and commercializing new drugs for treating tropical diseases. In recent years, the Company’s research and development efforts have focused on a new class of broad-spectrum antiviral drugs, including a new drug in Phase 3 clinical development for treating influenza, and new drug candidates for treating cancer.
About Romark Laboratories
Romark Laboratories, L.C. is a vertically integrated biopharmaceutical company committed to the discovery and development of innovative small molecule drugs for treating infectious diseases and cancers. The Company markets Alinia® (nitazoxanide) tablets, 500 mg in the United States through a specialty sales force focused on gastroenterologists and primary care physicians.
Romark is developing a class of small molecule drugs called thiazolides. The Company’s product, NT-300 (nitazoxanide), is presently undergoing Phase 3 clinical development on a global basis for treatment of acute uncomplicated influenza. The NT-300 development program is being conducted under contract HHSO100201300004C with the U.S. Department of Health and Human Services. Other new drugs from the Company’s platform technology are proposed for treatment of viral diseases and cancers.